Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | AS3MT | Q9HBK9 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL869687 | 0.86 | IDO1 (0.38) | MAOBCYP3A4IDO1AGXT | |
| SCHEMBL5545779 | 0.81 | MAOB (0.47) | MAOBMAOACYP19A1CYP3A4CASP1 | |
| SCHEMBL896415 | 0.78 | IDO1 (0.33) | MAOBCYP3A4IDO1AGXT | |
| SCHEMBL823910 | 0.78 | MAOB (0.44) | MAOBMAOACYP19A1CYP3A4CASP1 | |
| SCHEMBL633486 | 0.78 | MAOB (0.52) | MAOBMAOACYP19A1CYP3A4CASP1 | |
| SCHEMBL1348468 | 0.78 | MAOB (0.52) | MAOBMAOACYP19A1CYP3A4CASP1 | |
| SCHEMBL30601044 | 0.78 | MAOB (0.52) | MAOBMAOACYP19A1CYP3A4CASP1 | |
| SCHEMBL366865 | 0.77 | MAOB (0.56) | MAOBMAOACYP19A1CYP3A4CASP1 | |
| SCHEMBL17578926 | 0.77 | MRGPRX4 (0.45) | MRGPRX4CYP11B1CYP11B2TP53 | |
| SCHEMBL896416 | 0.77 | IDO1 (0.58) | MAOBMAOAALDH1A1TDP1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415338-B2 | Oxygen linked pyrimidine derivatives | CELL THERAPEUTICS, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415338-B2 | Oxygen linked pyrimidine derivatives | CELL THERAPEUTICS, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120196855-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2012-08-02 | — | — | US | disclosed |
| US-20120196855-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2012-08-02 | — | — | US | disclosed |
| EP-0885570-B2 | Cigarette with a dual-structure filter | JAPAN TOBACCO INC (JP) | 2007-04-04 | — | — | EP | disclosed |
| EP-0885570-B1 | Cigarette with a dual-structure filter | JAPAN TOBACCO INC (JP) | 2002-08-21 | — | — | EP | disclosed |
| US-6206007-B1 | Cigarette with a dual-structure filter | JAPAN TOBACCO INC. (JP) | 2001-03-27 | — | — | US | disclosed |
| EP-0885570-A1 | Cigarette with a dual-structure filter | JAPAN TOBACCO INC. (JP) | 1998-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196855-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | MAOB 983/4885MAOA 1396/4885CYP19A1 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.